Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation

详细信息    查看全文

• 作者：Dominic Leiser ; Beno卯t Pochon ; Wieslawa Blank-Liss ; Paola Francica ; Astrid A. Gl眉ck ; Daniel M. Aebersold ; Yitzhak Zimmer ; Michaela Medov谩
• 关键词：RTK ; receptor tyrosine kinase ; TKI ; tyrosine kinase inhibitor ; HGF ; hepatocyte growth factor ; wt ; wild type ; TKB ; tyrosine kinase binding
• 刊名：FEBS Letters
• 出版年：3 March, 2014
• 年：2014
• 卷：588
• 期：5
• 页码：653-658
• 全文大小：934 K

文摘

The MET receptor tyrosine kinase is deregulated primarily via overexpression or point mutations in various human cancers and different strategies for MET inhibition are currently evaluated in clinical trials. We observed by Western blot analysis and by Flow cytometry that MET inhibition by different MET small molecule inhibitors surprisingly increases in a dose-dependent manner total MET levels in treated cells. Mechanistically, this inhibition-related MET accumulation was associated with reduced Tyr1003 phosphorylation and MET physical association with the CBL ubiquitin ligase with concomitant decrease in MET ubiquitination. These data may suggest careful consideration for design of anti-MET clinical protocols.